Meijin Nakayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Meijin Nakayama has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Makito Okamoto
Department of Otorhinolaryngology, Kitasato University School of Medicine
37 shared publications Hiroomi Takahashi
23 shared publications- Hiromi Nagai
Department of Otolaryngology, Yamato Municipal Hospital, Yamato City, Kanagawa, Japan
20 shared publications - Kazuo Yao
From the Department of Otorhinolaryngolog y, Kitasato University, School of Medicine, Kanagawa, Japan
20 shared publications Tomohiro Makoshi
19 shared publications- Katsuhide Inagi
From the Department of Otorhinolaryngolog y, Kitasato University, School of Medicine, Kanagawa, Japan
11 shared publications
Latest Publications
- 1 January 2016
- Published by Japan Society for Head and Neck Surgery in JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY
- Vol. 25 (3) , 365-372
Endoscopy-assisted transpalatal resection of recurrent nasopharyngeal carcinoma
- 1 January 2016
- Published by Japan Society for Head and Neck Surgery in JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY
- Vol. 25 (3) , 365-372
Endoscopy-assisted transpalatal resection of recurrent nasopharyngeal carcinoma
- 1 January 2011
- Published by Japan Society for Head and Neck Surgery in JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY
- Vol. 20 (3) , 195-200
Partial maxillectomy assisted by nasal endoscopy
- 1 January 2011
- Published by Japan Society for Head and Neck Surgery in JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY
- Vol. 20 (3) , 195-200
Partial maxillectomy assisted by nasal endoscopy
- 1 January 2010
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 36 (1) , 119-124
Treatment indication for advanced head and neck cancer associated with psychiatric diseases
- 1 January 2010
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 36 (1) , 119-124
Treatment indication for advanced head and neck cancer associated with psychiatric diseases
- 1 September 2009
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 141 (3) , P162-P163
SP166 – SCL-CHEP: Pathological evidence withstands minimal margins
- 1 September 2009
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 141 (3) , P162-P163
SP166 – SCL-CHEP: Pathological evidence withstands minimal margins
- 1 January 2008
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 34 (3) , 352-354
Concurrent chemoradiotherapy for T2N0 glottic cancer
- 1 January 2008
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 34 (3) , 352-354
Concurrent chemoradiotherapy for T2N0 glottic cancer
- 2 November 2007
- Vol. 27, 3497-500
Effectiveness of concurrent radiation therapy with UFT or TS-1 for T2N0 glottic cancer in Japan.
The aim of this retrospective study was to compare concurrent radiation therapy (RT) combined with peroral chemotherapy (UFT or TS-1) with conventional RT for T2N0 glottic cancer. Between 1974 and 2005, 153 patients with T2N0 glottic cancer were treated with radiation alone or radiation combined with peroral (UFT or TS-1) or intravenous chemotherapy. All except one patient were treated with 2 Gy per fraction, 5 fractions per week, totaling 60 Gy; and the remaining patient was treated with 1.8 Gy per fraction, 5 fractions per week, totaling 61.2 Gy. Eighty-three patients were concurrently given UFT, 24 were given TS-1, 23 intravenous chemotherapy (mainly cisplatin; the Pt Group), and 23 had no chemotherapy. The 5-year local control rate was 83.4%. Stratified by RT alone (the RT group) and concurrent chemoradiation therapy (the CCRT group), 5-year local control rates of the RT and CCRT groups were 82.7% and 83.4%, respectively (p=NS). Stratified by chemotherapy regimens of the CCRT group, 3-year local control rates of the UFT, TS-1 and Pt groups were 90.1%, 100.0% and 73.4%, respectively. Concurrent chemoradiation therapy using UFT or TS-1 for T2N0 glottic cancer is one of the standard treatments in Japan. Concurrent use of TS-1 could be a breakthrough treatment for T2N0 glottic cancer.
- 2 November 2007
- Vol. 27, 3497-500
Effectiveness of concurrent radiation therapy with UFT or TS-1 for T2N0 glottic cancer in Japan.
The aim of this retrospective study was to compare concurrent radiation therapy (RT) combined with peroral chemotherapy (UFT or TS-1) with conventional RT for T2N0 glottic cancer. Between 1974 and 2005, 153 patients with T2N0 glottic cancer were treated with radiation alone or radiation combined with peroral (UFT or TS-1) or intravenous chemotherapy. All except one patient were treated with 2 Gy per fraction, 5 fractions per week, totaling 60 Gy; and the remaining patient was treated with 1.8 Gy per fraction, 5 fractions per week, totaling 61.2 Gy. Eighty-three patients were concurrently given UFT, 24 were given TS-1, 23 intravenous chemotherapy (mainly cisplatin; the Pt Group), and 23 had no chemotherapy. The 5-year local control rate was 83.4%. Stratified by RT alone (the RT group) and concurrent chemoradiation therapy (the CCRT group), 5-year local control rates of the RT and CCRT groups were 82.7% and 83.4%, respectively (p=NS). Stratified by chemotherapy regimens of the CCRT group, 3-year local control rates of the UFT, TS-1 and Pt groups were 90.1%, 100.0% and 73.4%, respectively. Concurrent chemoradiation therapy using UFT or TS-1 for T2N0 glottic cancer is one of the standard treatments in Japan. Concurrent use of TS-1 could be a breakthrough treatment for T2N0 glottic cancer.
- 1 January 2007
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 100 (4) , 303-307
Methicillin-Resistant Staphylococcus aureus (MRSA) Medication with Head and Neck Tumor
Following is the Otorhinolaryngology Department report, by Kitasato University Hospital, on the use of arbekacin sulfate (ABK) and vancomycin hydrochloride (VCM) for treating methicillin-resistant Staphylococcus aureus (MRSA). From March 2005 to February 2006, we performed retrospective research on 13 cases treated with either ABK or VCM. The subjects were 13 cases in which MRSA was detected in this institute's Otorhinolaryngology Department. The cases were evaluated for effectiveness, safety and economy. VCM treatment tended to show superior efficacy over ABK treatment, but safety was found to be equal. Anti-MRSA agents were administered for 8.6 days to the ABK group, and for 10.2 days to the VCM group. The ABK group costs tended to be lower. Considering patient background, the dosage, administration period, and other relevant factors, we concluded that either ABK or VCM may be equally recommended for the initial treatment of MRSA patients.
- 1 January 2007
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 100 (4) , 303-307
Methicillin-Resistant Staphylococcus aureus (MRSA) Medication with Head and Neck Tumor
Following is the Otorhinolaryngology Department report, by Kitasato University Hospital, on the use of arbekacin sulfate (ABK) and vancomycin hydrochloride (VCM) for treating methicillin-resistant Staphylococcus aureus (MRSA). From March 2005 to February 2006, we performed retrospective research on 13 cases treated with either ABK or VCM. The subjects were 13 cases in which MRSA was detected in this institute's Otorhinolaryngology Department. The cases were evaluated for effectiveness, safety and economy. VCM treatment tended to show superior efficacy over ABK treatment, but safety was found to be equal. Anti-MRSA agents were administered for 8.6 days to the ABK group, and for 10.2 days to the VCM group. The ABK group costs tended to be lower. Considering patient background, the dosage, administration period, and other relevant factors, we concluded that either ABK or VCM may be equally recommended for the initial treatment of MRSA patients.
- 1 January 2007
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 100 (1) , 43-46
Tetanus Associated with Trismus: A Case Report
We report a case of tetanus with trismus. A 44-year-old man presented with difficulty in mouth opening. Progressive trismus, stiffness of cervical muscles, convulsions, and a history of trauma indicated a diagnosis of tetanus. Emergency tracheotomy was performed because of convulsions against sedatives and difficulty in endotracheal intubation. The patient was given benzylpenicillin-potassium and antitetanus serum. He had respiratory distress for 23 days, and was discharged on the 45th hospital day.
- 1 January 2007
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 100 (1) , 43-46
Tetanus Associated with Trismus: A Case Report
We report a case of tetanus with trismus. A 44-year-old man presented with difficulty in mouth opening. Progressive trismus, stiffness of cervical muscles, convulsions, and a history of trauma indicated a diagnosis of tetanus. Emergency tracheotomy was performed because of convulsions against sedatives and difficulty in endotracheal intubation. The patient was given benzylpenicillin-potassium and antitetanus serum. He had respiratory distress for 23 days, and was discharged on the 45th hospital day.
- 1 January 2006
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 99 (4) , 299-304
Clinical Review of Laryngeal Cancer: a Series of 626 Cases over the Past 33 Years
Treatment modalities of laryngeal cancer have enormously evolved since 1971, the year our university hospital opened. In the 1970's, there were only two treatment options: radiation therapy and surgery. Chemotherapy and laser surgery were employed in the 1980's and organ preservation surgery, supracricoid laryngectomy with cricohyoidoepiglottopexy and cricohyoidopexy (SCL-CHEP and CHP), were introduced in 1997 at Kitasato University Hospital. This paper reviewed the clinical data of 626 patients over the past 33 years. Special interest was focused on the survival rates and ratio of laryngeal preservation over different treatment eras (early stage 1971-1982, mid stage 1983-1993, recent stage 1994-2004).Five-year crude and cause-specific survival rates for all laryngeal cancer patients were 76% and 85% respectively.Five-year cause-specific survival rates for 456 patients with glottic cancers were 91% (early stage), 91% (mid stage), and 89% (recent stage). Survival rate was already at the upper level and there was no marked difference among the different eras. Introduction of chemotherapy did not significantly contribute to improvement of the survival rate.The ratios of laryngeal preservation were 68%, 81%, 83% for early, mid, and recent stages, respectively. Chemoradiotherapy, introduced after the mid stage, has played a major role in laryngeal preservation.Organ preservation surgery, SCL-CHEP and SCL-CHP, played a major role in the recent stage for treating cases of radiation failure or selected cases of advanced diseases.UICC staging for laryngeal cancer was revised in 2002. Special attention must be paid to classifying the T3 stage based on the clinical features and CT images in order to choose the proper treatment modalities.
- 1 January 2006
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 99 (4) , 299-304
Clinical Review of Laryngeal Cancer: a Series of 626 Cases over the Past 33 Years
Treatment modalities of laryngeal cancer have enormously evolved since 1971, the year our university hospital opened. In the 1970's, there were only two treatment options: radiation therapy and surgery. Chemotherapy and laser surgery were employed in the 1980's and organ preservation surgery, supracricoid laryngectomy with cricohyoidoepiglottopexy and cricohyoidopexy (SCL-CHEP and CHP), were introduced in 1997 at Kitasato University Hospital. This paper reviewed the clinical data of 626 patients over the past 33 years. Special interest was focused on the survival rates and ratio of laryngeal preservation over different treatment eras (early stage 1971-1982, mid stage 1983-1993, recent stage 1994-2004).Five-year crude and cause-specific survival rates for all laryngeal cancer patients were 76% and 85% respectively.Five-year cause-specific survival rates for 456 patients with glottic cancers were 91% (early stage), 91% (mid stage), and 89% (recent stage). Survival rate was already at the upper level and there was no marked difference among the different eras. Introduction of chemotherapy did not significantly contribute to improvement of the survival rate.The ratios of laryngeal preservation were 68%, 81%, 83% for early, mid, and recent stages, respectively. Chemoradiotherapy, introduced after the mid stage, has played a major role in laryngeal preservation.Organ preservation surgery, SCL-CHEP and SCL-CHP, played a major role in the recent stage for treating cases of radiation failure or selected cases of advanced diseases.UICC staging for laryngeal cancer was revised in 2002. Special attention must be paid to classifying the T3 stage based on the clinical features and CT images in order to choose the proper treatment modalities.
- 1 January 2006
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 99 (12) , 1035-1039
Hepatocellular Carcinoma Metastasized to Palatine Tonsil: A Case Report
- 1 January 2006
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 99 (12) , 1035-1039
Hepatocellular Carcinoma Metastasized to Palatine Tonsil: A Case Report